Collegium Pharmaceutical (COLL) H.C. Wainwright 27th Annual Global Investment Conference summary

Business overview and financial performance

• Operates in pain management and ADHD, with $600M in pain net sales and $140M–$145M in ADHD net sales expected for the year.

• Full-year net sales guidance raised to $745M–$760M, with EBITDA margin nearing 60%.

• Maintains a disciplined capital deployment strategy: acquisitions, share repurchases, and debt reduction.

• Over $220M returned to shareholders since 2021; new $150M repurchase program authorized through 2026.

• Leverage expected to fall below 1x net debt/EBITDA by year-end, supporting future acquisitions.

ADHD franchise (JORNAY PM) growth drivers

• JORNAY PM is the only ADHD medication dosed at night, offering unique benefits for morning symptom control.

• Recent sales force expansion and increased physician engagement are driving awareness and uptake.

• Back-to-school season and improved gross-to-net dynamics support strong second-half performance.

• Prescriptions and prescribers up 23% year-over-year; market share also at 23%.

• Direct-to-consumer investments target parents and caregivers to further boost demand.

Commercial strategy and reimbursement

• Sales force expanded from 125 to 180, increasing target physicians and engagement frequency.

• DTC campaigns aim to raise awareness among caregivers, leveraging strong physician receptivity.

• JORNAY PM enjoys 65% commercial and 35% Medicaid coverage, with aggressive copay programs to offset costs.

• Continues to pursue expanded coverage only when economically viable.